National Health Investors (NYSE:NHI) was downgraded by stock analysts at Berenberg Bank from a “buy” rating to a “hold” rating in a report released on Wednesday, The Fly reports.
Several other analysts also recently issued reports on NHI. Stifel Nicolaus reiterated a “hold” rating and issued a $63.00 price target on shares of National Health Investors in a report on Tuesday, September 1st. ValuEngine downgraded National Health Investors from a “hold” rating to a “sell” rating in a research note on Thursday, October 1st. Finally, Zacks Investment Research upgraded National Health Investors from a “sell” rating to a “hold” rating in a research note on Thursday, November 19th. Two analysts have rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $65.88.
Shares of NYSE NHI opened at $65.46 on Wednesday. National Health Investors has a 12-month low of $31.37 and a 12-month high of $91.12. The company has a market cap of $2.93 billion, a P/E ratio of 15.37 and a beta of 0.79. The company has a current ratio of 13.13, a quick ratio of 13.13 and a debt-to-equity ratio of 1.02. The stock has a fifty day moving average price of $60.94 and a 200 day moving average price of $60.73.
National Health Investors (NYSE:NHI) last announced its quarterly earnings results on Monday, November 9th. The real estate investment trust reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.48). National Health Investors had a net margin of 56.94% and a return on equity of 12.64%. The company had revenue of $84.30 million during the quarter, compared to analyst estimates of $82.87 million. During the same quarter in the prior year, the company posted $1.42 earnings per share. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, sell-side analysts forecast that National Health Investors will post 5.63 EPS for the current fiscal year.
The firm that called the Exact Peak of the Dot-Com boom has just issued another major prediction.
If you’ve got money invested in the market – and especially in popular tech stocks – this is critical information for the days ahead…
In other National Health Investors news, Director Robert G. Adams bought 1,000 shares of the business’s stock in a transaction on Tuesday, November 17th. The shares were purchased at an average price of $66.45 per share, with a total value of $66,450.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.74% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Private Advisor Group LLC bought a new position in National Health Investors in the second quarter worth about $31,000. Marshall Wace North America L.P. bought a new position in National Health Investors in the first quarter worth about $31,000. Avantax Advisory Services Inc. bought a new position in National Health Investors in the third quarter worth about $202,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of National Health Investors during the third quarter valued at approximately $209,000. Finally, GSA Capital Partners LLP bought a new stake in shares of National Health Investors during the third quarter valued at approximately $210,000. 62.41% of the stock is currently owned by hedge funds and other institutional investors.
National Health Investors Company Profile
Incorporated in 1991, National Health Investors, Inc (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI’s portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals.
Featured Story: How to trade on quiet period expirations
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Ever since the U.S. economy began to re-open (and honestly before that), there was concern over the impending “second wave” of the novel coronavirus. And although the second wave of the virus was not expected to hit until the fall, the concerns have been escalating as case numbers rise in multiple states.
And despite the Trump administration’s vehement statements that the economy would not shut down, we learned on February 25 that Texas was now pausing, and in some cases rolling back, its reopening measures in an effort to stem the spread of the virus.
And this is happening as the Centers for Disease Control (CDC) is now saying that it’s possible that 20 million Americans may have the coronavirus based on a sample of blood tests that are showing who has the antibodies in their system.
For its part, the stock market reacted sharply to the move. It was a move that undoubtedly frustrated many weary investors. In fact, you might be among those that have had just about enough of the Covid-19 market. I understand, I’m there too.
But, institutional investors are forward-looking. And right now, they don’t like what they see. So stocks are having another broad selloff.
However, in the midst of any selloff, there is money to be made. And the good news for investors is that many of the same stocks that were good buys in March are still the stocks to buy right now. And while some of these stocks fit the classic definition of defensive stocks, you’ll find a few genuine growth stocks included on this list as well.